Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com
StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Free Report) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a […]
StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Free Report) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a […]
